A phase I study of PXL 770 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs PXL 770 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Proof of concept
- Sponsors Poxel
- 20 Sep 2017 According to a Poxel media release, the company has initiated a multiple ascending dose (MAD) trial for PXL770 and subjects have been dosed. The MAD trial will include up to 76 subjects and evaluate the safety, tolerability and pharmacokinetics of PXL770 in at least four dose groups. Completion of the MAD trial is anticipated in early 2018.
- 03 Apr 2017 According to a Poxel media release, company plans to initiate the multiple ascending dose portion of the Phase 1 study during the second half of 2017.
- 27 Jan 2017 According to a Poxel media release, the company anticipates to continue the study during the second half of this year.